

PRESS RELEASE

27 October 2023 11:45:00 CEST

Senzime shares begin trading on the US-based OTCQX Market

Senzime, an industry leader in algorithm-based patient monitoring solutions, announces that the Senzime shares (OTCQX: SNZZF) begin trading today on the OTCQX Market in the US. Senzime's shares will in parallel to its current Nasdaq Main Market listing in Stockholm, be traded with a US ticker symbol and a share price in USD.

OTC Markets Group operates financial markets for 12,000 US and global securities. OTCQX is a trading platform in the US operated by the OTC Markets Group, as an alternative to listing on Nasdaq New York and NYSE. Cross-trading on OTCQX helps satisfy an increasing interest from US investors and increase accessibility to the US capital market. Companies on OTCQX meet high financial standards, follow best practice corporate governance, demonstrate compliance with US securities laws, and have a professional third-party sponsor introduction.

"We're excited to begin trading on the OTCQX Market in the US and expand the reach beyond our Nasdaq Stockholm listing. Senzime has a strong base of international shareholders and with US being our most important commercial market, we now welcome the ability for more investors to join our leading journey towards a world free from postoperative complications", comments Philip Siberg, CEO of Senzime.

"We are pleased to welcome Senzime to the OTCQX Best Market," said Joe Coveney, Vice President of OTC Market Group's Corporate Services. "Senzime will trade alongside other leading life science and medical device companies that utilize a 'list local, trade global' strategy to leverage their home market filings and disclosures to publicly trade in the US and expand their global investor base."

Senzime was sponsored for OTCQX by B. Riley Securities, a qualified third-party firm responsible for providing guidance on OTCQX requirements and recommending membership.

For further information, please contact:

Philip Siberg, CEO of Senzime AB

Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Slavoljub Grujicic, CFO

Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Sensime

Sensime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Sensime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Sensime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at sensime.com.

Attachments

Sensime shares begin trading on the US-based OTCQX Market